Loading viewer...
investor_presentation
Format: PDF investor_presentation
1Halozyme Therapeutics, Inc. First Quarter 2024 Financial & Operating Results NASDAQ: HALO May 7, 2024
1Halozyme Therapeutics, Inc.
First Quarter 2024 Financial & Operating Results
May 7, 20242Forward Looking Statements
In addition to historical information, the statements set forth in this presentation include
forward -looking statements including, without limitation, statements concerning the
Company’s expected future growth, financial performance (including the Company’s
2024 guidance and longer term financial outlook through 2028) and expectations for
profitability, revenue (including expectations for future royalties, milestones and product
sales, and revenue durability and diversification), EBITDA, Adjusted EBITDA, non -GAAP
diluted earnings -per-share, expected growth rates of the Company’s partnered products,
potential share repurchases and the Company’s plans to potentially expand the
Company's platform through acquisitions. Forward -looking statements regarding the
Company’s ENHANZE®drug delivery technology include the possible benefits and
attributes of ENHANZE®including its potential application to aid in the dispersion and
absorption of other injected therapeutic drugs and facilitating more rapid delivery and
administration of higher volumes of injectable medications through subcutaneous delivery
and potential to decrease treatment burden, infusion related reactions and healthcare
system costs and enable new treatment sites. Forward -looking statements regarding the
Company's business may also include potential growth driven by our partners'
development and commercialization efforts (including anticipated ENHANZE®indication
and product approvals and launches and the timing related to these events), projections
for future sales revenue and market share of our collaborators’ products, potential new or
expanded ENHANZE®collaborations, collaborative targets and indications for ENHANZE®
products, the potential for co -formulation patents to extend royalty payment periods and
maintain royalty rates, and the Company’s plans to develop a high volume auto -injector
(including statements related to potential future development, approval and patient
treatment benefits of a high volume auto -injector). These forward -looking statements are
typically, but not always, identified through use of the words “expect,” "believe," "enable,"
"may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of similar meaning and involve
Preview truncated — download the full document for the complete content.
conference
20 Pages
investor_presentation
68 Pages
Tyler Technologies